新闻

RapAdmin

Researchers at the University of Colorado Anschutz Medical Campus took muscle biopsies from nineteen healthy men, nine sedentary and ten meeting the standard 150 minutes per week activity guideline, and profiled their skeletal muscle with high resolution respirometry, metabolomics, stable isotope tracing, and a graded cycling test. Sedentary muscle showed reductions of 28 to 36 percent across the electron transport chain, 51 percent lower CPT1 activity, lower cardiolipin, and a 49 percent reduction in MPC1, the mitochondrial pyruvate carrier. Glucose uptake machinery (GLUT4) and cytosolic lactate enzymes (LDHA, LDHB) were unchanged.

Physical inactivity is linked to more than five million deaths a year, and the usual explanation is close to circular: sedentary people are unfit, and unfit people get sick. A team at the University of Colorado Anschutz Medical Campus went looking for something more specific, and what they report sits inside the mitochondria of ordinary muscle.

They took vastus lateralis biopsies from nineteen healthy men, nine who did no structured exercise and ten who met the standard 150 minutes a week guideline. Nobody was diabetic. Nobody had cardiovascular disease. On paper, everyone was healthy. The tissue went through high resolution respirometry, mass spectrometry, and isotope tracing, and the men then rode a bike to exhaustion.

Sedentary muscle was worse at nearly everything, which is not the surprise. The pattern of the deficit is. The machinery that pulls glucose out of the blood was untouched. GLUT4, the glucose transporter, was present in identical amounts in both groups, as were the two enzymes that interconvert pyruvate and lactate. The failure was one step further in. MPC1, half of the gate that carries pyruvate across the inner mitochondrial membrane, was down by roughly half in the sedentary men. It was the largest single difference in the study.

The picture is a traffic problem. Sugar still enters the muscle cell normally. It is still broken down to pyruvate normally. But the door into the mitochondrion, where that pyruvate would be burned, appears narrower. Pyruvate backs up, gets shunted to lactate, and spills into the blood. On the bike, the sedentary men reached five millimoles of lactate at a workload where the active men were still below two.

The same story repeats on the fat side. CPT1, which loads long chain fatty acids into mitochondria, ran at about half the activity in sedentary muscle. Cardiolipin, the lipid that holds the respiratory chain in working formation, was also lower. Both fuels are being kept out of the furnace.

The authors are careful, and the caution matters. They cannot say whether the shrunken pyruvate gate causes the decline or simply reflects having fewer mitochondria per gram of muscle. They never counted mitochondria, which is the measurement that would settle it. And because this compares two groups of people at a single moment, it cannot establish whether inactivity produced the phenotype or whether people with better mitochondria are more inclined to exercise in the first place.

What the work does offer is a practical hook. Blood lactate and fat oxidation during submaximal cycling tracked the biopsy findings closely enough that the authors propose them as a non invasive readout of mitochondrial condition. Lactate above 2.5 millimoles combined with fat oxidation below 0.4 grams per minute at 50 to 60 percent of maximal oxygen uptake is their candidate signature of subclinical mitochondrial trouble.

That is a testable proposition rather than a validated test. It also rests, for now, on nineteen men.

Actionable Insights

Three things here are worth acting on.

First, the size of the gap. Statisticians use Cohen’s d, which measures the distance between two group averages in units of the natural spread within a group. A d of 0.2 is small, 0.8 is large. This study reported 1.2 to 2.2. Translated into something intuitive: pick one sedentary man and one active man at random, and the active man has more mitochondrial pyruvate carrier protein about 93 percent of the time, and higher aerobic fitness about 94 percent of the time. These are not subtle differences.

Second, the dose associated with them was modest. The active group were not athletes. They did 150 minutes a week of aerobic exercise, the standard public health minimum, sustained for at least six months. Their aerobic fitness averaged around 46 mL/kg/min against 28 in the sedentary group.

Third, blood lactate during moderate exercise is a cheap proxy for what a biopsy showed. At 125 watts, sedentary men averaged 5.1 mM against 1.5 mM in active men, a 3.4 fold difference.

Implications:

The implication of these fitness differences in these two groups of men is significant. The Cohort is of healthy men, mean age 41.9 years. The US male period life table (SSA, 2023 data) gives a cumulative 10-year mortality of 4.2 percent for a man aged 42. Splitting that population average around a relative risk of 2:

  • Active group: roughly 3 percent chance of death in the decade
  • Sedentary group: roughly 6 percent

The relative difference is large. The absolute difference is about 3 percentage points, or roughly 1 excess death per 33 sedentary men over ten years. Ninety-four percent of the sedentary group will be alive at 52.

The important point is this; between age 42 and 52 the two groups are building a divergence, not paying for one. The mortality bill for this decade’s physiology arrives in the 60s and 70s.

Context and Source

RapAdmin

A Wellcome Sanger Institute team sequenced 810 tissue samples from 172 donors aged 0 to 93 and measured, for the first time in one consistent experiment, how fast DNA errors accumulate in 53 different human cell types. The headline result is that mutations pile up in a straight line across the entire lifespan in almost every tissue, including cells that never divide, but the speed of that line varies more than 18-fold between organs. Sperm precursors accrue about 3.5 mutations per year, neurons about 17 to 20, colon lining cells about 52, liver cells about 63, and sun-exposed skin several hundred.

For thirty years the study of somatic mutation has been hampered by a technical embarrassment: DNA sequencers make more errors than cells do. A method called duplex sequencing solved that by reading both strands of every DNA molecule separately and accepting a mutation only when both strands agree. The Sanger group has now applied it at scale, and the result is the closest thing biology has to a speedometer reading for every major cell type in the human body.

The big idea is that ageing at the genome level is not one process running at one speed. It is dozens of processes running at different speeds in different rooms of the same house, and we can now read every dial.

Three findings stand out. The first is that accumulation is linear. Mutations do not snowball late in life; they arrive at a steady rate from birth to death in most tissues. The team tested curved and exponential models explicitly and the straight line won. That is what you would see if the rate of DNA damage, the efficiency of repair and the accuracy of copying all held roughly constant across eighty years. It is a quietly deflating result for anyone hoping a late-life intervention could slam the brakes on a runaway process, because there is no runaway to stop.

The second is that cell division is not the main engine. Neurons and heart muscle cells, which essentially stop dividing in early life, still accumulate around 17 to 37 mutations a year, comparable to many tissues that renew constantly. Whatever damages DNA does not need the cell to be copying its genome to do it. That points instead at slow chemical decay of the DNA molecule itself, running in the background of every cell whether or not it is doing anything.

The third, and the most consequential for public health, is that tobacco smoke mutates organs far from the lung. The study finds smoking signatures in liver cells, heart muscle, kidney tubules and bladder lining. Smoke chemicals enter the bloodstream and mutate tissue systemically. Cardiac muscle cells, which barely divide and cannot be replaced, carry the mark, and the affected heart samples came from the left side, which receives blood directly from the lung.

There is also a genuine puzzle at the centre of the dataset. The single largest contributor to the body’s total mutation burden is a pattern called SBS5, present in every cell type in every person, found in every mammal studied, and with no known cause. It runs at ten times the normal rate in liver cells and is almost switched off in sperm precursors, and nobody can say why. The authors name identifying its mechanism as the top priority coming out of the work, a striking admission for a field this mature.

Finally, the result the field will argue about. If mutations cause cancer, tissues with higher mutation rates should be more cancer-prone. Outside skin, they largely are not. Something other than raw mutation count, most likely how many cells a tissue has, how much they can still divide, and when in life the mutations land, is setting cancer risk.

Actionable Insights

Do not smoke, and if you have smoked, understand the scope. This paper shows tobacco mutating the liver, heart, kidney and bladder, not just the lung. Bladder lining cells vary between people by an amount equal to roughly 33 years of average mutation accumulation, and the paper attributes most of that spread to a smoking-linked pattern. In liver cells the equivalent figure is about 25 years, in heart muscle about 31 years. For comparison, brain and naive immune cells vary by only 4 to 5 years between individuals. Smoking is not a modest contributor to this variance; it is the dominant one the study could identify.

Protect skin from ultraviolet light. Skin epidermis has the highest mutation rate of any cell type measured, several hundred per year against a body-wide median near 25, and its person-to-person variation is driven almost entirely by ultraviolet signatures.

Alcohol leaves a distinct mutational signature in mouth and oesophageal lining in some individuals.

Context and Source

  • Open Access Paper: A comprehensive atlas of somatic mutation rates and mutational signatures in normal human cells
  • Lead institution: Somatic Genomics Programme, Wellcome Sanger Institute, Cambridge, United Kingdom
  • Contributing countries: United Kingdom, Netherlands, Japan, United States
  • Journal: bioRxiv preprint, posted 29 August 2026
  • Journal Impact Evaluation This is a preprint server deposit, not a journal article, so the requested metric cannot be applied as specified. Stated in the required format for completeness:

RapAdmin

**A Dutch multiomics study of 47 muscle biopsies reports that roughly 56 percent of the gene expression changes that distinguish old muscle from young muscle are simply absent in older adults who have trained consistently for years. The preventable fraction is dominated by mitochondrial energy metabolism, including electron transport chain subunits, mitochondrial ribosomal proteins, and NAD+ pathway metabolites. The fraction that persists regardless of training clusters instead around synaptic transmission and WNT signalling, with no dominant pathway. A second finding is that trained older adults do not merely age more slowly at rest, they also respond to an acute exercise bout in a pattern that resembles young adults. **

For decades the standard picture of muscle aging has been a slow, uniform slide. Mitochondria falter, energy metabolism drifts, strength goes. A Dutch team has now taken that picture apart and found that it is really two pictures stacked on top of each other, and only one of them responds to exercise.

Georges Janssens, Riekelt Houtkooper and colleagues at Amsterdam UMC and Maastricht University recruited 47 people and took muscle biopsies from the thigh. Eleven were in their twenties. The other 36 were over 65 and were sorted by how much they actually moved: 16 long-term exercisers averaging around 14,000 steps a day plus at least three training sessions a week, 15 people living an ordinary active life at roughly 9,600 steps, and five with measurable physical impairment. Everyone then rode a stationary bike for an hour at half their personal maximum and gave a second biopsy immediately afterwards. Every sample was run through three molecular readouts at once: more than 24,000 gene transcripts, 135 metabolites and 1,383 individual lipid species.

The headline number is the split. Comparing the young group with the ordinary older group produced a long list of genes that change with age. When the same comparison was run against the trained older group, roughly 56 percent of those changes were not there. Their muscle had not aged less in every respect. It had failed to age in a specific respect.

What falls into the preventable half is telling. It is dominated by the machinery of energy production: electron transport chain components such as NDUFS1 and COX5A, and a cluster of mitochondrial ribosomal proteins that build the respiratory apparatus itself. The metabolite data pointed the same way, with NAD+ pathway compounds among the ten most age-altered molecules, alongside triglyceride buildup inside the muscle fibre.

The unavoidable half looks nothing like it. Those genes cluster around synaptic transmission and WNT signalling, meaning the wiring between nerve and muscle and the developmental programmes that maintain tissue structure. No single pathway dominates, which the authors read as drift rather than a targetable process.

The second finding may matter more in practice. Aging did not just blunt the response to that hour on the bike, it distorted it. Ordinary older adults depleted and accumulated metabolites at four to six times the rate of the young, and accumulated four times as many altered lipid species. The trained older adults responded in a pattern closer to the young, and their inflammatory signalling genes, including IL6 and IL1B, fired harder than in their sedentary peers, not softer. Fitness bought a stronger stress response, not a quieter one.

The caveat is structural and the authors state it. Nobody was randomised. These are people who chose to train for decades, in a country where cycling is ordinary and where the sedentary comparison group still walks close to 10,000 steps a day. The trained group was also about three years younger and leaner. What the study establishes is that half of the muscle aging signature is compatible with being absent, and where the other half lives.

Actionable Insights

Maintaining regular, structured endurance training preserves cellular energy production into late life. Casual daily walking is insufficient to safeguard mitochondrial capacity; older participants logging 9,600 steps per day still experienced widespread bioenergetic decline, whereas individuals completing at least three 1-hour structured exercise sessions weekly maintained youthful muscle profiles.

The magnitude of this protective benefit is substantial. Exercise prevented 55.9% of normal age-related gene upregulations and 57.1% of age-related gene downregulations. For mitochondrial respiratory complex I and complex V gene expression, training kept median transcript counts within approximately 5% to 10% of young levels, contrasting with a 30% to 50% decrease seen in untrained older adults. Standardized effect sizes across respiration markers and clinical stamina indices between trained and untrained individuals regularly exceeded 1.2 standard deviations (Cohen’s d).

Practical guidance highlights the necessity of reaching genuine cardiovascular exertion rather than merely accumulating low-intensity steps. In addition, practitioners must be cautious with non-specific, long-term anti-inflammatory interventions: the transient inflammatory and stress response provoked by exercise is an indispensable signal that drives tissue remodeling and cellular resilience in aging muscle.

Context/Source

RapAdmin

An economics-led team applied unsupervised machine learning to fifty years of Global Burden of Disease data and re-sorted 304 diseases not by their biology but by the age at which they strike. Four natural groups emerged: infant, early-adult, later-adult and aging-related. The aging-related group is now the largest single source of health loss on the planet, it is the largest expected lifetime burden facing a newborn in every income bracket, and it behaves differently from the other three in two measurable ways. Its diseases kill and disable the same people at the same time, and the payoff from reducing them grows as you reduce them.

For half a century global health has run on a simple storyline. Poor countries lose children to infection, rich countries lose adults to heart disease and cancer, and development moves a nation from one state to the other. Abdel Omran named it the epidemiological transition in 1971, and it has shaped where money goes ever since. A new analysis in Nature Aging argues the storyline is wrong in an important way.

The research team, led by economists Julian Ashwin and Andrew Scott alongside global health figures David Bloom and Peter Piot, took Global Burden of Disease data covering 304 diseases and injuries across 204 countries from 1990 to 2023 and did something unusual. Instead of sorting conditions into the standard bins of communicable and non-communicable, they let an algorithm sort them by when in life they strike. The method, K-means++ clustering, was given a single input: how much health loss each disease causes per person at each age.

Four groups fell out. Infant diseases, including measles, malaria and diarrhoeal illness. Early-adult diseases, including HIV, road injuries and maternal conditions. Later-adult diseases, including most cancers and much of mental illness. And a fourth group whose burden climbs with age and then stays high: ischaemic heart disease, chronic obstructive pulmonary disease, type 2 diabetes, chronic kidney disease and dementia.

That fourth cluster is now the largest single category of disease burden in the world. Its share has grown from roughly a quarter in 1990 to a little over two-fifths today, while the infant share has fallen from just above half to below thirty per cent. The classification holds steady across three decades.

Two properties make the aging cluster distinctive. First, the diseases that kill are largely the same ones that disable, so there is no tradeoff between adding years and adding healthy years. Second, and this is the paper’s central claim, the returns to fighting these diseases rise as progress is made. Because aging-related conditions accumulate in the same bodies, preventing one raises the value of preventing the next. Halve their prevalence and the gain is about 2.2 times what a quarter reduction buys by 2050, rising to 3.2 times by 2100. Remove them entirely, a hypothetical the authors use as a ceiling rather than a plan, and global life expectancy would rise by 17.4 years, past ninety.

Insights

First, the ceiling. Removing every aging-related disease worldwide would add 17.4 years to average life expectancy, roughly a 24 per cent gain on a base near 73 years. Removing all infant, early-adult and later-adult disease combined would add 5.3 years. The aging cluster is worth about 3.3 times all other life stages put together. That is the size of the prize, and it is a theoretical maximum, not an achievable target.

Second, the compounding. Halving the prevalence of aging-related disease buys about 2.2 times what a quarter reduction buys, not the 2.0 times a straight line would predict. That 10 per cent premium is the measurable value of stacking prevention across multiple systems rather than one condition at a time. By 2100 the same comparison is 3.2 versus 2.0, a 60 per cent premium.

Third, no tradeoff. For aging-related diseases the correlation between how much a disease kills and how much it disables is 0.59. For early-adult diseases it is 0.26. In plain terms, the strongest lever on lifespan and the strongest lever on healthspan are the same lever.

Context and Source

  • Paper: Aging rises, yet the double burden of illness remains. Published 2 September 2026.
  • Institutions: Maastricht University, Netherlands; Harvard T.H. Chan School of Public Health and NBER, USA; Ellison Institute of Technology, Oxford, UK; London School of Hygiene and Tropical Medicine, UK; London Business School, UK; Centre for Economic Policy Research, France. Access status:
  • Journal: Nature Aging (Springer Nature).
  • Impact: The impact score of this journal is 25.0, evaluated against a typical high-end range of 0-60+ for top general science, therefore this is a High impact journal.

RapAdmin

Four researchers from Sanford Burnham Prebys and Stanford argue that age-related muscle loss has finally become a tractable drug target. Sarcopenia now has a diagnostic code, a consensus clinical definition, and a mechanistic map spanning mitochondrial failure, blocked autophagy, stem cell exhaustion, nerve withdrawal, chronic inflammation, and vascular decay. The authors survey the therapeutic pipeline built on that map: NAD+ precursors, urolithin A, oleuropein, mTOR inhibitors, myostatin and activin antibodies, selective androgen receptor modulators, apelin and VEGF agonists, and inhibitors of the enzyme 15-PGDH, which the senior author’s laboratory named a “gerozyme.” Their central warning is that gains in muscle mass have repeatedly failed to produce gains in muscle strength, and that the explosion of GLP1 weight loss drugs is now creating sarcopenia risk at population scale.

For most of the last century, losing muscle as you age was treated as scenery rather than pathology. That framing is now gone. Sarcopenia received an ICD-10 code in 2016 and a consensus clinical definition in 2019, and with those two administrative facts came insurance reimbursement, trial endpoints, and pharmaceutical interest. A new review in Nature Reviews Drug Discovery takes stock of what that interest has produced.

The numbers that motivate the field are unforgiving. After 50, people lose roughly 10 percent of their muscle mass per decade. Between 40 and 80, somewhere between 30 and 50 percent of skeletal muscle is gone. Up to one in ten people across 26 surveyed countries meets criteria for sarcopenia. In 2014 the United States spent more than 40 billion dollars on hospitalizations in which nearly half the burden traced back to muscle wasting.

The big idea in the review is that muscle wasting is not one failure but a network of them, and that single-target drugs have kept failing for exactly that reason. Mitochondria in aged muscle swell, lose cristae, leak calcium, and accumulate DNA damage. The mTORC1 pathway is stuck in the “on” position yet somehow fails to build protein, while simultaneously shutting down the cellular recycling that clears damaged mitochondria. Motor neurons retreat from the muscles they once controlled. Muscle stem cell numbers fall by 24 percent in women and 37 percent in men, and two-thirds of the survivors are functionally broken. Fast-twitch fibres, the ones that catch you when you trip, shrink by about 40 percent while slow fibres barely change.

Against that, the authors line up a pipeline. Some entries are supplements already on shelves, including urolithin A, nicotinamide riboside, trigonelline, and the olive polyphenol oleuropein. Some are repurposed drugs, including rapamycin analogues and the arthritis drug tofacitinib. The most commercially advanced are antibodies that block myostatin and activin, which reliably grow muscle in mice and reliably underdeliver in humans.

The authors’ own preferred candidate belongs to a category they invented a word for. A “gerozyme” is an enzyme that becomes more active with age and spends that activity destroying something the body needs. Their example is 15-PGDH, which degrades prostaglandin E2. Force it into young muscle and the muscle ages. Block it in old mice and, according to the review, muscle strength, nerve connections, cartilage, blood, and even the blood-brain barrier improve together. A drug based on this idea has cleared phase I safety testing. The senior author cofounded the company developing it, a disclosure the paper states openly.

The sharpest section concerns GLP1 receptor agonists. Semaglutide and tirzepatide strip 25 to 30 percent of adipose tissue, but lean tissue leaves with it, and when the drug stops, fat returns while muscle does not. With roughly 13 percent of the world living with obesity and a projected billion by 2030, that asymmetry is a public health problem in the making. Several companies are now running combination trials pairing weight loss drugs with muscle-preserving antibodies.

The authors end on an unresolved tension. The field can add muscle. It has not reliably added strength. Until trials measure force and function rather than kilograms, the pipeline’s promise stays theoretical.

Actionable Insights

The single most useful takeaway is a benchmarking one: the review states plainly that exercise plus adequate protein is the standard every drug in this pipeline is measured against, and most drugs lose.

Concrete magnitudes worth knowing:

Myostatin-blocking antibodies, the most advanced muscle drugs in human testing, produce muscle mass gains of 3 to 9 percent with “limited functional improvements.” For a person carrying 28 kg of lean mass, that is roughly 0.8 to 2.5 kg. Supervised resistance training in older adults typically delivers a similar mass change plus large strength gains that the drugs do not match.

Fast-twitch fibres shrink about 40 percent with age while slow fibres are largely spared. Training that only involves walking or steady cardio does not address the fibre type actually being lost. Loaded, explosive, or heavy work does.

If you use a GLP1 receptor agonist, treat muscle preservation as part of the protocol rather than an optional extra. Fat loss of 25 to 30 percent comes with lean tissue loss, and after discontinuation fat returns faster than muscle.

On supplements: human evidence for urolithin A and NAD+ precursors is real but modest, and one mouse experiment in this review found that cutting muscle NAD+ by 85 percent produced no measurable muscle deficit at all.

Context and Source

  • Paywalled Paper: Strengthening muscle for healthy ageing: innovative treatments for sarcopenia
  • Authors: Sara Ancel, Emmeran Le Moal, Yu Xin Wang, Helen M. Blau (Ancel and Le Moal contributed equally)
  • Institutions: Center for Cardiovascular and Muscular Diseases, Sanford Burnham Prebys Medical Discovery Institute, San Diego, California, USA; Baxter Laboratory for Stem Cell Biology, Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, California, USA. Present addresses include Nestlé Institute of Health Sciences (Lausanne, Switzerland) and Regeneron Pharmaceuticals (Tarrytown, New York, USA).
  • Country: United States, with Swiss industry affiliation
  • Journal: Nature Reviews Drug Discovery
  • Publication date: Published online 07 September 2026.
  • Article type: Review article, peer reviewed.
  • Impact evaluation: The impact score of this journal is 91.2 (2025 Journal Impact Factor, publisher-reported; 5-year JIF 131.3), evaluated against a typical high-end range of 0 to 60+ for top general science, therefore this is an Elite impact journal.

相关阅读:

RapAdmin

Beyond Plain Water: How Everyday Kitchen Staples Slash Produce Pesticides by Half

A systematic scoping review analyzing 47 peer-reviewed studies across 23 produce matrices and 79 pesticides evaluated common domestic decontamination strategies. The analysis demonstrated that while plain water rinsing and soaking achieve modest median reductions of 30.2% and 33.7% respectively, active kitchen washes using sodium bicarbonate (baking soda) or diluted acetic acid (vinegar) significantly outperform plain water, achieving median pesticide concentration reductions of 50.9% and 54.2%. Chemical clearance efficiency is strictly bounded by pesticide systemic absorption, lipophilicity, and the presence of natural or applied cuticular wax layers.

Diets rich in fruits and vegetables remain fundamental to cardiovascular and metabolic longevity, yet commercial produce serves as the primary route of civilian exposure to synthetic agrochemicals. Regulatory surveillance, such as the USDA Pesticide Data Program, rinses produce under cold running water for 15 to 20 seconds before testing, an approach that assumes standard home prep will clear significant surface burden. However, comprehensive quantitative synthesis reveals this baseline assumption is overly optimistic.

Analyzing 1,100 extracted data points across global literature, researchers evaluated four consumer practices: cold water rinsing, plain water soaking, soaking in sodium bicarbonate solutions, and soaking in acetic acid or vinegar. Running water rinses, lasting an average of 41 seconds, achieved an overall median pesticide reduction of just 30.2%. Static water soaking for an average of 11 minutes performed marginally better at 33.7%.

The primary barrier to clearance is chemical behavior at the surface boundary. Hydrophobic compounds, characterized by high octanol-water partition coefficients, migrate rapidly into plant cuticles or artificial wax coatings. Highly lipophilic compounds such as lambda-cyhalothrin resist displacement by plain water, remaining embedded in external tissues. Similarly, systemic compounds like azoxystrobin and acetamiprid translocate beneath the epidermis into the vascular system, rendering internal residues physically inaccessible to standard washing.

Introducing active alkaline or acidic solutions substantially alters this dynamic. Baking soda solutions achieved a median reduction of 50.9%, whereas vinegar solutions demonstrated a median removal of 54.2%. These agents enhance the degradation and dislodgement of complex agrochemicals, outperforming plain water rinsing by an absolute margin of 20 to 24 percentage points. Nevertheless, complete elimination of chemical residues was rare across all modalities. While active kitchen soaks significantly lower cumulative xenobiotic intake, structural produce characteristics and pesticide mobility place hard physical limits on how much toxic burden can be eliminated at the sink.

Actionable Insights

Do not rely on quick running water rinses to clean non-organic produce. A 15 to 40 second cold water rinse leaves roughly 70% of detectable pesticide mass on conventional produce.

Soaking produce in a mild alkaline or acidic solution provides a substantial, measurable improvement in residue clearance. Adding either dissolved sodium bicarbonate or diluted distilled vinegar to a produce soak improves pesticide removal from a baseline of roughly 30% to over 50%. In practical terms, this intervention eliminates an additional 20% to 24% of the starting pesticide residue, cutting consumer dietary exposure roughly in half compared to eating produce straight from the store.

Soak firm produce for 10 to 15 minutes before consumption. For smooth, hard-surfaced produce such as apples, tomatoes, and peppers, an alkaline soak accelerates surface breakdown of non-systemic chemicals. However, recognize the biological limits: porous, high-surface-area items like strawberries and leafy greens absorb chemicals internally, where washing solutions cannot reach. For these thin-skinned items, prioritize organic purchasing to prevent internal agrochemical deposition entirely.

Context/Source

  • Full Title: Reducing pesticide residues on produce: a scoping review of household produce washing methods
  • Institution: Environmental Working Group, Washington, DC, United States
  • Country: United States
  • Journal Name: Frontiers in Environmental Health
  • Impact Evaluation: The impact score of this journal is 2.0 (CiteScore), evaluated against a typical high-end range of 0 to 60+ for top general science, therefore this is a Low impact journal.

RapAdmin

Three Norwegian exercise physiologists compared how fast VO2peak declines with age when measured two different ways: by testing many people of different ages once (cross-sectional), versus testing the same people repeatedly over years (longitudinal). The cross-sectional literature, which is what almost every clinical reference chart is built from, produces the familiar figure of roughly 10 percent lost per decade, holding steady across the lifespan. The longitudinal literature says something different and worse. Decline is not linear. It accelerates. After age 70 it reaches 15 to 20 percent per decade in women and 20 to 25 percent per decade in men. The gap between the two designs is largest exactly where it matters most clinically, in the oldest patients, and the likely cause is survivor bias: the 80-year-olds who show up for a maximal treadmill test were never average 40-year-olds.

There is a number that shows up in nearly every discussion of aerobic fitness and aging: 10 percent per decade. It is tidy, it is memorable, and according to this review it is wrong in the age range where it gets used most.

The problem is architectural. To build a fitness reference chart you need thousands of people, so researchers recruit a wide age range, test everyone once, and draw a line through the results. That line is a snapshot of different people, not a trajectory of one person. It compares today’s 30-year-olds to today’s 80-year-olds, and the 80-year-olds in that room are a survivor population. Low fitness predicts death and disease with unusual reliability, so the people who were unfit at 50 are disproportionately absent from the 80-year-old group. What looks like a gentle slope is partly a filter.

Follow the same individuals instead and the slope steepens. Two large longitudinal cohorts, the Baltimore Longitudinal Study of Aging in the United States and the HUNT Study in Norway, tracked participants across a wide age range and reported results by decade. Both found acceleration. Both found the acceleration is worse in men. In men past 70, aerobic capacity falls by roughly a quarter every ten years.

The designs disagree in a specific, age-dependent pattern. In young adults, cross-sectional estimates run slightly high. Through middle age the two converge. After about 60 the longitudinal estimates pull decisively ahead. One repeated-measures study of older adults put the annual loss at 0.69 mL/kg/min per year in men when tracked over time, against 0.34 when estimated across ages, a factor of two.

The clinical consequence is direct. A physician following a patient’s fitness over a decade, and comparing it against a cross-sectional chart, will see a normal-looking decline and reassure. The patient may in fact be losing capacity at the expected longitudinal rate, which is far larger, or at an abnormal rate hidden inside a too-generous expectation. Trajectory needs a trajectory-derived reference.

The review also leaves a hard finding sitting in plain sight. In the Generation 100 trial, 1567 adults over 70 were followed for five years, and VO2peak fell about 2 percent per year after the first year in the supervised exercise groups and the control group alike, despite training volume being maintained. Twenty percent per decade, with the exercise already priced in.

Actionable Insights

Four things follow from this paper.

First, your own previous test result is a better benchmark than any age-matched chart, particularly after 60. Charts built from one-time testing of many people understate how fast a real person declines.

Second, expect acceleration. Planning around a steady 10 percent per decade will overestimate where you land at 80. A man testing with a VO2Max at 31 mL/kg/min at age 70 would project to about 25 by age 90 under the 10 percent rule, but to roughly 17 under the observed 25 percent rule. That difference of about 8 mL/kg/min is more than 2 METs, and 18 mL/kg/min is near the level where daily independent living becomes effortful.

Third, the size of a fitness difference is worth knowing in risk terms. One MET, which is 3.5 mL/kg/min, is associated with roughly 13 percent lower all-cause mortality and 15 percent lower cardiovascular event risk in meta-analysis. The measurement-design gap alone, about 3.5 mL/kg/min per decade in older men, is one whole MET.

Fourth, and least comfortable: in the one large randomized trial cited, five years of supervised training in over-70s produced a VO2peak advantage over controls of 0.76 mL/kg/min. That is a small effect, worth about a year of delay in decline. Peak aerobic reserve built before 60 appears to matter more than training started after 70. Build the VO2Max ceiling early.

Context and Source

  • Open Access Paper: Age-related decline in peak oxygen uptake: Cross-sectional vs. longitudinal findings. A review., 2023 Jan 13.
  • Institution: Department of Circulation and Medical Imaging, Norwegian University of Science and Technology (NTNU), Trondheim, with St. Olavs University Hospital, Norway, and the University of Queensland, Australia.
  • Country: Norway (with Australian affiliation).
  • Journal: International Journal of Cardiology Cardiovascular Risk and Prevention.
  • Journal impact evaluation: This journal is a companion title to International Journal of Cardiology and does not carry a confirmed Clarivate Journal Impact Factor in the JCR core collection.

相关阅读:

RapAdmin

A 49-year-old Lithuanian ultra-endurance runner covered 30,303 km in 444 days, averaging 68 km per day, and a research consortium led by Lithuanian Sports University phenotyped him before, throughout, and for 17 months afterwards using muscle biopsies, ultrasonography, dynamometry, blood panels, and stool microbiome sequencing. The headline result is a dissociation: endocrine, haematological, and cardiac systems held up remarkably well, while skeletal muscle absorbed nearly all the damage. Muscle thickness fell 6 to 13 percent, maximal knee extension torque fell 23 percent, explosive power fell 34 to 50 percent, and fibre composition shifted to near-total slow-twitch dominance. Markers of muscle damage, oxidative stress, autophagy, apoptosis, and inflammation were all elevated at the finish, alongside suppressed IGF-1 and elevated GDF8 (myostatin). Mitochondrial electron transport chain proteins and mitochondrial quality-control regulators were lowest at the finish and rose progressively over the following 17 months, indicating that mitochondrial recovery from this load takes more than a year. Reactive strength never fully recovered.

A 49-year-old Lithuanian runner set out to cover 30,300 km, roughly three-quarters of the way around the planet, and did it in 444 days. That works out to 68 km a day, about nine hours of running, nearly every day, for close to fifteen months. A team based at Lithuanian Sports University tracked him the whole way and for seventeen months afterwards, taking blood at 24 timepoints, stool samples at thirteen, and four muscle biopsies from his thigh.

The big idea in their report is that the body tolerated this far better in some systems than others, and that skeletal muscle was the system that paid. Hormones held steady. Testosterone stayed at or above his pre-run level, which the authors flag as surprising, since polar expeditions and comparable extreme events usually suppress it. Red cell counts, haemoglobin, blood glucose, and heart structure all stayed within normal bounds. He lost only three kilograms, and most of that was fat.

Muscle was another story. Thigh muscle thickness fell by 6 to 13 percent depending on the site. Maximal voluntary knee extension torque dropped 23 percent. Explosive measures collapsed: jump height fell by 44 to 51 percent, and the reactive strength index, which captures how well a leg behaves like a spring, fell from 0.80 to 0.25, a 69 percent loss. His muscle became almost entirely slow-twitch, with type I fibres at 98 percent or more, leaving essentially nothing to generate speed or power.

Creatine kinase, a marker of muscle membrane damage, spiked fifteen-fold in the first month and never returned to baseline, sitting about three times above his starting level for the remainder of the event. Liver enzymes and a marker of lipid peroxidation stayed elevated too. IGF-1, an anabolic signal, was reduced at most timepoints; GDF8, better known as myostatin and a brake on muscle growth, rose. The muscle was being instructed to break down and not rebuild.

Recovery took time. Isometric strength returned to baseline by ten months. Mitochondrial proteins climbed steadily and were still rising at seventeen months, which suggests the biopsy taken at the finish caught a genuinely depleted engine rather than a transient dip. Reactive strength never came back. His gut bacteria shifted as well, with Bifidobacterium enriched during the run and Akkermansia during recovery, and those shifts persisted rather than snapping back.

One runner, no control group, no baseline biopsy. This is a description of what happened to one exceptional man, not a finding about people in general.

Actionable Insights

The lesson here is dose, not direction. Endurance running is good for you; nine hours a day of it for a year is a catabolic stimulus.

The magnitudes, expressed as percentage change from his own pre-challenge values:

  • Explosive power fell 34 to 50 percent (squat jump power 40.6 to 26.9 W/kg, drop jump power 42.9 to 21.6 W/kg). Leg power normally declines roughly 3 to 4 percent per year after age 50. He lost the equivalent of about a decade of aging in fifteen months.
  • Maximal isometric strength fell 23 percent (278 to 215 Nm), roughly twenty years of typical age-related decline.
  • Thigh muscle thickness fell 5.5 to 12.6 percent, and thigh circumference fell 7.7 percent.
  • Reactive strength, the springiness of the leg, fell 69 percent and was still 29 percent below baseline seventeen months later. This was the one thing that did not recover.
  • Body fat fell from 13 to 9.7 percent during the run, then overshot to 17.1 percent at ten months, a 43 percent relative increase in fat mass above where he started.

Three practical take-homes. First, if you train high volume, keep resistance work and any form of jumping in the program; it is the fast, elastic qualities that vanish first and return last. Second, watch iron: his ferritin stayed low despite continuous oral supplementation and one intravenous infusion. Third, expect fat overshoot after a large sustained deficit and plan the return to normal eating rather than improvising it.

Context and Source

  • Open Accesss Paper: Musculoskeletal (Mal)adaptations in Response to a >30 000-km Running Challenge
  • Lead institution: Institute of Sport Science and Innovations, Lithuanian Sports University, Kaunas, Lithuania. Co-authoring institutions include Lithuanian University of Health Sciences (Lithuania), Örebro University and Karolinska Institutet (Sweden), and INSERM/Université de Toulouse (France).
  • Journal: Journal of Cachexia, Sarcopenia and Muscle (Wiley), 2026.
  • Impact evaluation: The impact score of this journal is 9.9 (2025 Journal Impact Factor; the value has ranged from 8.9 to 9.9 over 2022 to 2025), evaluated against a typical high-end range of 0 to 60+ for top general science, therefore this is a High impact journal.

RapAdmin

Five senior investigators at the US National Institute on Aging propose that tissue aging is driven not by a linear chain of damage but by a closed feedback circuit. Stiffening of the extracellular matrix reduces blood flow and oxygen delivery; the resulting hypoxia forces cells to throttle their own mitochondria via HIF-1 signaling; the ensuing ATP and NAD+ shortfall starves repair machinery and pushes cells into senescence; senescent cells then secrete the exact enzymes that stiffen the matrix further, closing the loop. The authors call this the senescence-stiffening loop and argue it explains why aging tissues lose the capacity to sense stress, adapt, and repair. This is a Perspective article. It contains no new experimental data.

Aging research has spent two decades cataloguing hallmarks. This Perspective from Luigi Ferrucci’s group at the National Institute on Aging attempts something different: it wires several of those hallmarks into a single circuit and argues that the circuit, rather than any one component, is what makes a tissue old.

The circuit starts with the extracellular matrix, the collagen and elastin scaffold that every cell sits inside. With age that scaffold stiffens. Lysyl oxidase enzymes weld collagen fibers together, sugars form permanent glycation cross-links, elastin fragments, capillary basement membranes thicken, and the endothelial glycocalyx thins. A stiff matrix means vessels cannot dilate on demand and new capillaries fail to sprout. Capillary density falls. Tissue oxygen supply falls with it.

Then comes the metabolic step, and this is the paper’s most interesting move. Low oxygen stabilizes HIF-1, which deliberately shuts mitochondria down: PDK1 blocks pyruvate from entering the TCA cycle, NDUFA4L2 suppresses complex I, and complex IV swaps subunits. That is a sensible short-term protective response and a catastrophic long-term one, because glycolysis cannot fund protein quality control, DNA repair, or the constant ion pumping that keeps cells alive. ATP and NAD+ decline, sirtuins lose their fuel, damaged mitochondria fragment and leak their DNA and oxidized cardiolipin, and those fragments trip the cGAS-STING and NLRP3 alarms. Cells go senescent. Their secretions include the matrix enzymes that started the story.

Two arguments lift this above a tidy narrative. The first uses human mitochondrial disease as a natural experiment: fast, Leigh-type disease kills neurons outright with little fibrosis, whereas slow mitochondrial disease of liver, muscle, and heart reliably produces fibrosis. That pattern suggests chronic energy failure actively drives matrix remodeling rather than merely accompanying it.

The second addresses a real puzzle. Population averages of cognition and mobility decline roughly linearly, yet individuals often report a cliff. The authors argue that redundancy buffers the loop invisibly for years until buffering capacity is exhausted, and that frailty is what that failure looks like from the outside.

Therapeutically, they point to entry points on every arc: senolytics and senomorphics, cross-linking inhibitors, anti-glycation compounds, glycocalyx repair, NAD+ and PGC-1alpha support, exercise, and even supplemental oxygen.

Insights

What it does change is which measurements matter. The loop’s earliest and most measurable link is vascular: arterial stiffness and capillary function precede the metabolic collapse. Arterial stiffness is cheaply measurable as pulse wave velocity, and the external literature the paper builds on is where the real magnitudes live. In pooled observational meta-analysis, people in the high aortic pulse wave velocity group carry roughly twice the risk of cardiovascular events and death compared with the low group, and each 1 m/s increase associates with roughly 14 to 15 percent higher risk.

The only intervention in the paper credited with acting on multiple arcs of the loop simultaneously is endurance exercise, which the authors say reverses microvascular rarefaction, improves glycocalyx integrity, and reduces matrix glycation in animals. Glycemic control matters for the same reason: glycation cross-links are permanent and cumulative.

Everything else listed, including senolytics, lysyl oxidase inhibitors, anti-glycation agents, and hyperbaric oxygen, is named as investigational. Treat it as a research agenda.

Context and Source

  • Open Access Paper: The senescence-stiffening loop: Extracellular matrix remodeling, hypoperfusion, and mitochondrial dysfunction drive tissue aging
  • Authors: Luigi Ferrucci, Stefano Donega, Allison B. Herman, Rafael de Cabo, Myriam Gorospe
  • Institution: National Institute on Aging, National Institutes of Health, Baltimore, Maryland.
  • Country: United States
  • Journal: Cell Metabolism, volume 38, September 1, 2026.
  • Impact Score: The impact score of this journal is 37.0 (most recently reported Journal Impact Factor; Scopus CiteScore 40.7), evaluated against a typical high-end range of 0 to 60+ for top general science, therefore this is an Elite impact journal.

相关阅读:

RapAdmin

Researchers tracking brain tissue from the decades-long Lothian Birth Cohort 1936 discovered that human cognitive decline is unexpectedly driven by an accumulation of dysfunctional oligodendrocytes, which wrap nerve fibers in excessively thick, disordered myelin sheaths. These abnormal cells exhibit a marked loss of the master antioxidant regulator NRF2. Modeling this cell-specific defect in mice confirmed that deleting oligodendroglial NRF2 directly triggers hypermyelination, shrinks nerve fiber diameter, and blunts cognitive learning over time.

For decades, neuroscientists viewed age-related cognitive decline primarily through the lens of dying neurons, toxic protein aggregates, or the progressive stripping away of myelin—the specialized fatty insulation that coats central nervous system axons. Without sufficient myelin, electrical transmission slows and circuits degrade. A study published in Nature Medicine turns this assumption on its head, demonstrating that an overabundance of poorly regulated myelin can be just as destructive as demyelination.

Using post-mortem tissue from the Lothian Birth Cohort 1936, a landmark Scottish study tracking mental ability from age 11 into the ninth decade of life, investigators probed the corpus callosum to evaluate structural differences between individuals with preserved cognition and those suffering steep decline. High-resolution electron microscopy revealed that brains with severe mental decline did not lack myelin. Instead, they displayed an unexpected accumulation of oligodendrocytes that produced pathologically thick myelin sheaths around large nerve fibers. This structural distortion went hand-in-hand with an increased prevalence of empty, degenerating axons and shrunken fiber calibers, indicating that excess, abnormal insulation actively strangles or starves the underlying neuronal wiring.

Single-nucleus transcriptomic profiling revealed the driver behind this pathology. The accumulated oligodendrocytes suffered from a severe deficit of NRF2, a transcription factor that orchestrates cellular defenses against oxidative damage, maintains mitochondrial homeostasis, and governs macroautophagy. Rather than dying, these defective glial cells persisted and downregulated critical autophagic turnover genes, causing abnormal membrane build-up.

To determine whether oligodendroglial NRF2 deficiency is a causal driver rather than a passive byproduct of brain aging, the team engineered a conditional mouse model in which NRF2 was selectively deleted from oligodendrocytes in middle age. The rodents recapitulated the exact structural defects seen in human brains: thickened myelin coats, shrunken axon diameters, and impaired spatial learning in water maze tests. These findings firmly reclassify the oligodendrocyte from a benign support cell into an active mediator of age-related cognitive deterioration.

Actionable Insights While this research relied on post-mortem human tissue and genetic mouse models rather than clinical lifestyle interventions, it identifies a clear target for preserving white matter health: maintaining active NRF2 signaling in the aging brain.

  • Upregulate Endogenous NRF2 Activity: Because the pathological cascade begins when oligodendrocytes downregulate NRF2, maintaining this pathway via dietary electrophilic compounds (such as sulforaphane from broccoli sprouts) or therapeutic activators (such as dimethyl fumarate) represents a logical preventative strategy.

  • Support Autophagic Clearance: The downstream consequence of low NRF2 in these cells is suppressed autophagy (noted by reduced SQSTM1/p62 expression), which prevents normal turnover of bulky myelin membrane. Interventions that stimulate cellular recycling pathways may help curb aberrant membrane deposition.

  • Magnitude of the Effect: The functional impact of losing oligodendroglial NRF2 is substantial. In aged mice, normal controls improved their spatial learning efficiency by an average of 57.75% across consecutive training days, whereas mice lacking oligodendroglial NRF2 improved by only 27.82%. This represents an absolute drop in learning improvement of 29.93 percentage points, cutting their learning gains roughly in half (a relative deficit of 51.8%). In human tissue, the proportion of oligodendrocytes expressing functional NRF2 dropped from approximately 87% in individuals with mild cognitive decline down to roughly 65% in severe decline.

Context/Source

  • Full Title: Oligodendrocyte dysfunction in human age-related cognitive decline
  • Lead Institutions: Keenan Research Centre for Biomedical Science, Unity Health Toronto, and The University of Edinburgh
  • Countries: Canada, United Kingdom, and United States
  • Journal Name: Nature Medicine
  • Impact Evaluation: The journal impact factor is 58.7 (Journal Citation Reports, 2024–2025; CiteScore 72.8). The impact score of this journal is 58.7, evaluated against a typical high-end range of 0–60+ for top general science, therefore this is an Elite impact journal.

相关阅读: